Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
J Am Geriatr Soc. 2012 Oct;60(10):1854-61. doi: 10.1111/j.1532-5415.2012.04165.x. Epub 2012 Sep 24.
To assess the effect of exposure to evidence-based medication after hospital discharge for Medicare beneficiaries with acute myocardial infarction (AMI).
A discrete-time hazard model was used to estimate time to outcome associated with exposure to four drug classes (angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin-II receptor blockers (ARBs), beta-blockers (BBs), statins, and clopidogrel) used for post-AMI secondary prevention of cardiovascular events and mortality.
Medicare administrative data for a 5% random sample of beneficiaries.
Medicare beneficiaries (N = 9,538) hospitalized for an AMI between April 1, 2006, and December 31, 2007, who survived for at least 30 days after discharge. The cohort was followed until death or December 31, 2008.
Time-varying exposure was measured as proportion of days covered (PDC) for each quarter during the follow-up period. PDC was classified into five categories (0-0.2, 0.2-0.4, 0.4-0.6, 0.6-0.8, 0.8-1.0). Outcomes were mortality and a composite outcome of death or post-AMI hospitalization.
Over a median follow-up of 18 months, mean PDC rates ranged from 0.37 (clopidogrel) to 0.50 (statins). When comparing the highest versus lowest categories of exposure, the hazard of the composite outcome was significantly lower for all drug classes except BBs (statins, adjusted hazard ratio (aHR) = 0.71, ACEIs/ARBs, aHR = 0.81, clopidogrel, aHR = 0.85, BBs, aHR = 0.93). All four drug classes were significantly associated with reductions in mortality; the magnitude of effect for the mortality outcome was largest for statins and smallest for BBs. Age modified the effect of statins on mortality.
Use of evidence-based medications for secondary prevention after AMI is suboptimal in the Medicare population, and low exposure rates are associated with significantly higher risk for subsequent hospitalization and death.
评估在接受医疗保险的急性心肌梗死(AMI)患者出院后接受基于证据的药物治疗的效果。
使用离散时间风险模型来估计与暴露于四种药物类别(血管紧张素转换酶抑制剂(ACEI)/血管紧张素 II 受体阻滞剂(ARB)、β受体阻滞剂(BB)、他汀类药物和氯吡格雷)相关的结局的时间,这些药物类别用于预防 AMI 后心血管事件和死亡率的二级预防。
医疗保险管理数据,针对随机抽取的 5%的受益人。
医疗保险受益人(N=9538),2006 年 4 月 1 日至 2007 年 12 月 31 日期间因 AMI 住院治疗,出院后至少存活 30 天。该队列随访至死亡或 2008 年 12 月 31 日。
时间变化的暴露被测量为随访期间每季度的覆盖率(PDC)。PDC 分为五类(0-0.2、0.2-0.4、0.4-0.6、0.6-0.8、0.8-1.0)。结局是死亡率和 AMI 后住院治疗的复合结局。
在中位随访 18 个月期间,平均 PDC 率范围从 0.37(氯吡格雷)到 0.50(他汀类药物)。与暴露的最高和最低类别相比,除 BB 外,所有药物类别的复合结局风险均显著降低(他汀类药物,调整后的危险比(aHR)=0.71,ACEI/ARB,aHR=0.81,氯吡格雷,aHR=0.85,BB,aHR=0.93)。所有四种药物类别均与死亡率降低显著相关;他汀类药物对死亡率的影响最大,而 BB 类药物的影响最小。年龄改变了他汀类药物对死亡率的影响。
在医疗保险人群中,AMI 后二级预防使用基于证据的药物的情况并不理想,低暴露率与随后住院和死亡的风险显著增加相关。